Tectonic Therapeutic, Inc.

NASDAQ:TECX

Biotechnology

Healthcare
$21.04 -0.96%

-$0.29 today

Market cap
$411.32M
Beta
1.22
P/E (TTM)
-6.7
EPS (TTM)
-$4.45
52W Low $14.39High $36.03

Volume 0.17M

Average 0.20M

TECX Interest Income

Income earned on cash, deposits, and investments held by the company.

Tectonic Therapeutic, Inc.NASDAQ: TECX

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income dips below year-ago levels

Q1 FY2026 interest income of $2.18M fell 10.8% year over year, behind the +71.1% change in trailing-twelve-month interest income. Sequentially, it fell 14.9% from the prior quarter. Over 3 fiscal years it compounded at +323.2% a year.

Context

  • Interest income increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -10.8% toward the trailing-twelve-month pace of +71.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.18M-14.9% QoQ
Last fiscal yearDec 2025
$11.3M+165.1% YoY
LTMMar 2026
$11.03M+71.1% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-10.8%——
1 year+165.1%——
3-year CAGR+323.2%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
11.3M USD
Year-over-year change
+165.1%

Interest Income vs competitors

How TECX compares with its peers on the latest reported figures

  • TECX's LTM Mar 2026 interest income of $11.03M is the lowest of the 4 companies compared; the peer median is $20.44M.
  • Its year-over-year change of +71.1% is the highest of 4, against a peer median of +10.1%.
  • Over three fiscal years its annual growth of +323.2% compares with a peer median of +206.0%.
TECX Competitors Peer median
Interest Income for TECX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GPCRStructure Therapeutics Inc.LTM Jun 2026$32.19M +10.1%+206.0%—
SEPNSepterna, Inc.LTM Sep 2026$20.44M +12.9%—21.2%
GENBGenerate Biomedicines, Inc.FY2025$13.66M -24.6%—42.8%
TECXTectonic Therapeutic, Inc.LTM Mar 2026$11.03M +71.1%+323.2%—
Peer median (excluding TECX) $20.44M+10.1%+206.0%32.0%

Competitors are the stored peer set for TECX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development10.98M25.65M36.97M41.36M63.49M
Selling, General & Admin4.63M7.18M7.68M16.65M20.55M
Operating Expenses15.61M32.83M44.65M58.02M84.04M
Depreciation & Amortization364K1.01M1.48M1.65M1.38M
EBITDA(8.12M)(31.03M)(41.19M)(56.23M)(71.48M)
EBITDA Margin—————
Operating Income(15.61M)(32.83M)(44.65M)(58.02M)(84.04M)
Operating Margin—————
Interest Income0149K581K4.26M11.3M
Interest Expense224K144K152K107K63K
Other Income / Expenses6.68M650K1.83M33K11.12M
Income Before Tax(8.93M)(32.18M)(42.82M)(57.98M)(72.92M)
Pre-Tax Margin—————
Income Tax Expense00001.23M
Net Income(8.93M)(32.18M)(42.82M)(57.98M)(74.15M)
Net Margin—————
EPS (Basic)(33.36)(29.05)(11.59)(3.93)(4.05)
EPS (Diluted)(33.36)(29.05)(11.53)(3.93)(4.05)
Weighted Avg Shares3.57M3.64M3.69M14.77M18.32M
Weighted Avg Shares (Diluted)3.57M3.64M3.71M14.77M18.32M

Tectonic Therapeutic, Inc.

NASDAQ:TECX

Intrinsic Alpha fair value

Locked

Current Price

$21.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.